Preferred Language
Articles
/
-niBTKABuRolNscLYe1W
Formulation and In Vivo Evaluation of Ticagrelor-Loaded Spanlastic Nanovesicles to Enhance Intestinal Absorption
...Show More Authors
Introduction:

Ticagrelor (TCG) is an effective P2Y12 receptor antagonist used to prevent atherothrombotic cardiovascular events; however, its poor solubility and limited permeability (BCS Class IV) restrict its oral bioavailability. Spanlastic Nanovesicles (SNVs), composed of nonionic surfactants and edge activators, offer a promising strategy to enhance drug solubility and permeability. This study aimed to develop and optimize TCG-loaded SNVs using the ethanol injection method, validate a sensitive HPLC method for TCG quantification, and evaluate the pharmacokinetic and antiplatelet performance of the optimized formulation in rats.

Method:

TCG-SNVs were prepared using the ethanol injection technique with a varying ratio of Span 60 and Tween 60. Formulations were characterized for Particle Size (PS), Polydispersity Index (PDI), and Encapsulation Efficiency (EE %). Morphology was examined by Transmission Electron Microscope (TEM). A reversed -phase HPLC method was validated for linearity, accuracy, precision, LOD, and LOQ. In vivo pharmacokinetic studies were conducted in Sprague-Dawley rats (10 mg /kg oral dose), and pharmacokinetic parameters (C max, Tmax, AUC, t 1/2) were determined. Inhibition of platelet aggregation was evaluated using a dual-channel aggregometer.

Results:

Among the tested formulations, SNV2 showed optimal characteristics with a particle size of 79.21 nm, PDI of 0.1213, and EE % of 86.87%. TEM confirmed spherical and uniformly distributed vesicles. The validated HPLC method demonstrated excellent linearity (100-800 ng/ml), high accuracy (mean recovery 99%), and acceptable precision (% RSD < 2%), with LOD and LOQ values of 8 ng/mL and 24.24 ng/mL in plasma, respectively. Pharmacokinetic analysis revealed significantly enhanced systemic exposure for SNV2 compared to the marketed product, with increased Cmax (9500 vs. 4500 ng/ml), AUC (115150 vs. 70107.5 ng/mL), reduced Tmax (4 vs. 8 hours), and a relative bioavailability improvement of 64.33%. Additionally, SNV2 demonstrated a greater reduction in ADP-induced platelet aggregation than the comparator formulation.

Discussion:

The improved pharmacokinetic and pharmacodynamic performance of SNV2 can be attributed to enhanced solubility, nanoscale size, high encapsulation efficiency, and improved intestinal permeability provided by the flexible spanlastic vesicles. The validated HPLC method ensures accurate and reliable quantification of TCG in plasma, supporting the robustness of the in vivo findings.

Conclusion:

TCG-loaded spanlastic nanovesicles prepared by the ethanol injection method significantly enhanced oral bioavailability and antiplatelet efficacy compared to the marketed formulation. The optimized SNV2 formulation represents a promising nanocarrier system for improving the therapeutic performance of ticagrelor and may offer potential clinical benefits in the management of cardiovascular diseases.

View Publication
Publication Date
Tue Jun 15 2021
Journal Name
Iraqi Journal Of Pharmaceutical Sciences ( P-issn 1683 - 3597 E-issn 2521 - 3512)
Nanosuspensions of Selexipag: Formulation, Characterization, and in vitro Evaluation
...Show More Authors

Selexipag is an orally selective long-acting prostacyclin receptor agonist, which indicated for the treatment of pulmonary arterial hypertension. It is practically insoluble in water ( class II, according to BCS). This work aims to prepare and optimized Selexipag nanosuspensions to achieve an enhancement in the in vitro dissolution rate. The solvent antisolvent precipitation method was used for the production of nanosuspension, and the effect of formulation parameters (stabilizer type, drug: stabilizer ratio, and use of co-stabilizer) and process parameter (stirring speed) on the particle size and polydispersity index were studied. SLPNS prepared with Soluplus® as amain stabilizer (F15) showed the smallest particle size 47nm wi

... Show More
View Publication Preview PDF
Scopus (38)
Crossref (17)
Scopus Crossref
Publication Date
Sat Nov 04 2023
Journal Name
Iraqi Journal Of Pharmaceutical Sciences( P-issn 1683 - 3597 E-issn 2521 - 3512)
Study the Effect of Formulation Variables on Preparation of Nisoldipine Loaded Nano Bilosomes
...Show More Authors

Nisoldipine (NSD) is a dihydropyridine class of calcium channel blockers used for hypertension treatment, it belongs to class II BCS (low solubility with high permeability), its absolute bioavailability is only 5% due to presystemic metabolism in the gut wall. It is also a substrate for a CYP3A and P-gp. Bilosomes are lipid bilayer vesicles incorporating bile salts in their walls to prevent degredation by GIT bile salts. The aim of this study is to prepare nisoldipine bilosomes as vesicular carrier and assess the effect of different formulation variables such as type of surfactant, amount of cholesterol, surfactant and sonication time on particle size, entrapment efficiency and poly dispersity index of the prepared bilos

... Show More
View Publication
Scopus (21)
Crossref (11)
Scopus Crossref
Publication Date
Mon Mar 03 2025
Journal Name
Journal Of Research In Pharmacy
Formulation and characterization of bilastine - cyclodextrin inclusion complex loaded as an oral fast dissolving film
...Show More Authors

Oral fast dissolving films (OFDFs) are the most innovative oral solid pharmaceutical dosage form, especially for elderly and pediatric patients who may have dysphagia. Bilastine (BLA), is a second – generation antihistamine used to manage allergy symptoms; it is very slightly soluble in water. The main objective of this research was to enhance the solubility and dissolution rate of BLA by complexation technique. Ternary complex of BLA: methyl β- cyclodextrin (M-β-CD): soluplus® 5% w/w was prepared via solvent evaporation technique as a trial to enhance its solubility to be prepared as OFDF by incorporated into aqueous polymeric solution. Seven formulas of OFDFs were prepared using the solvent casting method using

... Show More
View Publication Preview PDF
Scopus Crossref
Publication Date
Tue Mar 28 2017
Journal Name
Iraqi Journal Of Pharmaceutical Sciences ( P-issn 1683 - 3597 E-issn 2521 - 3512)
Formulation and Evaluation of Flurbiprofen Oral Film
...Show More Authors

Fast dissolving film can be defined as a dosage form, which when placed in the oral cavity. It will rapidly disintegrate and dissolves to release the medication for oral mucosal absorption or allow for the gastrointestinal absorption to be achieved when swallowed.

Flurbiprofen is non-steroidal anti-inflammatory agent with antipyretic and analgesic properties and can be used   in low doses 8.75 mg as analgesic and anti inflammatory agent in sore throat infection. This study aims to   formulate flurbiprofen as oral dissolving films,   to improve the effective relief of pain with severe sore throats with little or no adverse effect.

Nine formulas were prepared using solvent-casting method, and t

... Show More
View Publication Preview PDF
Crossref (4)
Crossref
Publication Date
Mon Jan 01 2024
Journal Name
Nanotechnology, Science And Applications
Formulation and Characterization of Intranasal Drug Delivery of Frovatriptan-Loaded Binary Ethosomes Gel for Brain Targeting
...Show More Authors

Background: Frovatriptan succinate (FVT) is an effective medication used to treat migraines; however, available oral formulations suffer from low permeability; accordingly, several formulations of FVT were prepared. Objective: Prepare, optimize, and evaluate FVT-BE formulation to develop enhanced intranasal binary nano-ethosome gel. Methods: Binary ethosomes were prepared using different concentrations of phospholipid PLH90, ethanol, propylene glycol, and cholesterol by thin film hydration and characterized by particle size, zeta potential, and entrapment efficiency. Furthermore, in-vitro, in-vivo, ex-vivo, pharmacokinetics, and histopathological studies were done. Results: Regarding FVT-loaded BE, formula (F9) demonstrated the best paramet

... Show More
View Publication
Scopus (32)
Crossref (26)
Scopus Clarivate Crossref
Publication Date
Sat Dec 11 2021
Journal Name
Iraqi Journal Of Pharmaceutical Sciences ( P-issn 1683 - 3597 E-issn 2521 - 3512)
Anastrozole Loaded Nanostructured Lipid Carriers : Preparation and Evaluation
...Show More Authors

Anastrozole (ANZ) is considered constitute of the fourth –generation of Non–steroidal aromatase blockage, ANZ has use for hormone receptor positive breast cancer in postmenopausal women. The serious side effects of ANZ including, vaginal dryness, hot flashes, irritability, breast tenderness and un–stability in circulation.

Nanostructured lipid carriers (NLCs) have recently emerged as a multifunctional platform for drug delivery in cancer therapy.

Five formula were composed of (200 mg of glyceryl monostearate, 40 mg of oleic acid , 1% (w/w) Tween 80, 1% (w/w) Poloxamer 407, 1% (w/w) soy lecithin and Vitamin E Polyethylene Glycol Succinate.

The mean particle size, polydispersity index, zeta potential, entrapme

... Show More
View Publication Preview PDF
Scopus (28)
Crossref (17)
Scopus Crossref
Publication Date
Mon Jun 01 2026
Journal Name
Egyptian Journal Of Agronomy
Field Performance Evaluation of Spring - Loaded Cultivator
...Show More Authors

View Publication
Scopus Crossref
Publication Date
Tue Aug 05 2014
Journal Name
International Journal Of Pharmacy And Pharmaceutical Sciences
FORMULATION AND EVALUATION OF FLOATING ORAL IN-SITU GEL OF METRONIDAZOLE
...Show More Authors

View Publication Preview PDF
Scopus (20)
Scopus
Publication Date
Sun Dec 22 2019
Journal Name
Iraqi Journal Of Pharmaceutical Sciences ( P-issn 1683 - 3597 E-issn 2521 - 3512)
Formulation and In-Vitro Evaluation of Darifenacin Hydrobromide as Buccal Films
...Show More Authors

         Darifenacin hydrobromide (DH) is the more recent uroselective M3 receptor antagonist for treating uncomplicated overactive bladder (OAB). This study was aimed to formulate DH as fast dissolving buccal films (FDBFs) using a solvent casting method to enhance patient’s compliance.

         Films were prepared by using polyvinyl alcohol (PVA) as a film forming polymer. Different types and concentrations of superdisintegrants (croscarmellose sodium, sodium starch glycolate, indion 414) were used to select the best formula by studying the physicochemical properties of the films, disintegration time (DT) and percent drug release.

 &nb

... Show More
View Publication Preview PDF
Scopus (26)
Crossref (13)
Scopus Crossref
Publication Date
Tue Jul 02 2024
Journal Name
Al-rafidain Journal Of Medical Sciences ( Issn 2789-3219 )
Formulation and Evaluation of Bilastine Thermosensitive Mucoadhesive Ophthalmic in situ Gel
...Show More Authors

Background: Bilastine is a non-sedating, second-generation antihistamine used to treat urticaria and allergic conjunctivitis. Objective: to formulate and test bilastine as a mucoadhesive ophthalmic in situ gel in order to extend its presence at site for longer time and help treat conjunctivitis and allergic rhinitis. Methods: We prepared formulations using different concentrations of poloxamers (Poloxamer 407 (P407) and Poloxamer 188 (P188)) in combination with hydroxypropyl methyl cellulose (HPMC). The prepared formulas were evaluated for their physicochemical properties, sol-gel transition temperature, viscosity, mucoadhesive strength, drug release, and kinetic modeling. Results: The prepared in situ gels were clear and transparen

... Show More
View Publication
Scopus (1)
Crossref (2)
Scopus Crossref